HDT Bio
HDT Bio is a clinical-stage biopharmaceutical company based in Seattle, developing novel technologies and products designed to harness and enhance the immune system for the treatment and prevention of cancer and infectious diseases. HDT Bio utilizes advanced immunotherapeutic platforms, including a proprietary nanoparticle delivery system, to provide safe, potent, and durable solutions that enable rapid clinical translation and personalized cancer therapies. The company's multidisciplinary team and international partnerships facilitate robust clinical development, innovative product design, and global distribution with the goal of improving patient outcomes worldwide.
Industries
Nr. of Employees
small (1-50)
HDT Bio is currently seeking investment
HDT Bio is seeking a seed investment in the range of 5m-20m
Patents
Products
Vaccine candidate targeting breast cancer using immunotherapeutic platform.
Immunotherapy vaccine candidate for glioblastoma based on targeted antigens.
Vaccine targeting prostate cancer antigens to elicit an immune response.
Immunotherapy platform-based candidate for prevention and treatment of pancreatic cancer.
RNA-based vaccine targeting SARS-CoV-2, demonstrating favorable safety and immunogenicity in clinical use.
Self-amplifying RNA, nanoparticle-delivered vaccine in clinical development for CCHF virus.
Vaccine candidate targeting breast cancer using immunotherapeutic platform.
Immunotherapy vaccine candidate for glioblastoma based on targeted antigens.
Vaccine targeting prostate cancer antigens to elicit an immune response.
Immunotherapy platform-based candidate for prevention and treatment of pancreatic cancer.
RNA-based vaccine targeting SARS-CoV-2, demonstrating favorable safety and immunogenicity in clinical use.
Self-amplifying RNA, nanoparticle-delivered vaccine in clinical development for CCHF virus.
Expertise Areas
- Immuno-oncology
- RNA and DNA-based vaccine development
- Nanoparticle drug delivery
- Infectious disease vaccine research
Key Technologies
- Self-amplifying replicon RNA
- Nanoparticle-based delivery systems
- Viral vector genome engineering
- TLR3 and RIG-I pathway activation
Key People
Director, Funding Management
Director, Funding Management
News & Updates
Study in preclinical models showing efficacy of a self-amplifying RNA vaccine against enterovirus D68.
Research article on multivalent replicating RNA vaccine with nanoparticle delivery.
Durability of protective immunity induced by a replicon RNA vaccine demonstrated in animal models.
Milestone announced in efforts to advance brain cancer immunotherapy research.
Initiation of a clinical program using immunotherapy for brain cancer at McGill University.
Awarded for development and advancement of a CCHF vaccine candidate from lab to clinical stage.
Study in preclinical models showing efficacy of a self-amplifying RNA vaccine against enterovirus D68.
Research article on multivalent replicating RNA vaccine with nanoparticle delivery.
Durability of protective immunity induced by a replicon RNA vaccine demonstrated in animal models.
Milestone announced in efforts to advance brain cancer immunotherapy research.
Initiation of a clinical program using immunotherapy for brain cancer at McGill University.
Awarded for development and advancement of a CCHF vaccine candidate from lab to clinical stage.